Abstract
Non alcoholic fatty liver disease (NAFLD) is defined as fat accumulation exceeding 5% to 10% by the weight of the liver, in the absence of other causes of steatosis. NAFLD is strongly associated with metabolic diseases, such as metabolic syndrome. At present, insulin resistance, elevated concentrations of free fatty acids and oxidants, and an imbalance between different cytokines have been identified as the common pathophysiological elements underlying both NAFLD and metabolic syndrome. Emerging evidence also considers NAFLD as the hepatic manifestation of metabolic syndrome and supports a possible direct role of fat liver in cardiovascular risk assessment. Further investigations are needed to better understand the role of NAFLD, as an independent active factor in metabolic syndrome and associated cardiovascular disease.
Keywords: Atherosclerosis, metabolic syndrome, non-alcoholic fatty liver disease, cardiovascular risk
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Does Non-Alcoholic Fatty Liver Disease (NAFLD) Increase Cardiovascular Risk?
Volume: 8 Issue: 4
Author(s): Fabrizio Montecucco and Francois Mach
Affiliation:
- Cardiology Division, Department of Medicine, Geneva University Hospital, Foundation for Medical Researches, 64 Avenue Roseraie, 1211 Geneva, Switzerland.,Switzerland
Keywords: Atherosclerosis, metabolic syndrome, non-alcoholic fatty liver disease, cardiovascular risk
Abstract: Non alcoholic fatty liver disease (NAFLD) is defined as fat accumulation exceeding 5% to 10% by the weight of the liver, in the absence of other causes of steatosis. NAFLD is strongly associated with metabolic diseases, such as metabolic syndrome. At present, insulin resistance, elevated concentrations of free fatty acids and oxidants, and an imbalance between different cytokines have been identified as the common pathophysiological elements underlying both NAFLD and metabolic syndrome. Emerging evidence also considers NAFLD as the hepatic manifestation of metabolic syndrome and supports a possible direct role of fat liver in cardiovascular risk assessment. Further investigations are needed to better understand the role of NAFLD, as an independent active factor in metabolic syndrome and associated cardiovascular disease.
Export Options
About this article
Cite this article as:
Montecucco Fabrizio and Mach Francois, Does Non-Alcoholic Fatty Liver Disease (NAFLD) Increase Cardiovascular Risk?, Endocrine, Metabolic & Immune Disorders - Drug Targets 2008; 8(4) . https://dx.doi.org/10.2174/187153008786848268
| DOI https://dx.doi.org/10.2174/187153008786848268 |
Print ISSN 1871-5303 |
| Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Allegations from Whistleblowers
- Publishing Ethics
- Increase Visibility Of Your Article
- Self Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Neuromodulation of the Perinatal Respiratory Network
Current Neuropharmacology Emerging Risk Factors for Cerebrovascular Disease
Current Drug Targets Drug Development and the Importance of Ethnicity: Lessons from Heart Failure Management and Implications for Hypertension
Current Pharmaceutical Design Lipid Raft in Cardiac Health and Disease
Current Cardiology Reviews Editorial (Thematic Issue: Cardiac Imaging in the Diagnosis of Coronary Artery Disease: A Comprehensive Overview of Various Imaging Modalities)
Current Medical Imaging Porphyrins in Photodynamic Therapy - A Search for Ideal Photosensitizers
Current Medicinal Chemistry - Anti-Cancer Agents Inflammation as the Common Biological Link Between Depression and Cardiovascular Diseases: Can Carnosine Exert a Protective Role?
Current Medicinal Chemistry Calcium Homeostasis and Kinetics in Heart Failure
Medicinal Chemistry ULK1 Plays a Critical Role in AMPK-Mediated Myocardial Autophagy and Contractile Dysfunction following Acute Alcohol Challenge
Current Pharmaceutical Design Novel Approaches to the Pharmacotherapy of Obesity
Current Pharmaceutical Design Caring for HIV-Infected Patients in the ICU in The Highly Active Antiretroviral Therapy Era
Current HIV Research Diagnostic and Therapeutic Nanoparticles in Cardiovascular Diseases
Current Pharmaceutical Design Aortic Stenosis, Aortic Regurgitation and Arterial Hypertension
Current Vascular Pharmacology Role of Heme Oxygenases in Cardiovascular Syndromes and Co-morbidities
Current Pharmaceutical Design Targeting FoxO1 for Hypertriglyceridemia
Current Drug Targets Autoimmune (Auto-inflammatory) Syndrome Induced by Adjuvants (ASIA) – Animal Models as a Proof of Concept
Current Medicinal Chemistry Intrauterine Intervention for the Treatment of Fetal Growth Restriction
Current Pediatric Reviews Myocardial Infarction. Pathological Relevance and Relationship with Coronary Risk Factors
Current Pharmaceutical Design Ethnic Differences in Pharmacogenetically Relevant Genes
Current Drug Targets Obesity and Arterial Compliance Alterations
Current Vascular Pharmacology




